• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioInvent International

24.20 SEK

-2.42 %

Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.42 %
+1.26 %
+4.31 %
-17.69 %
-14.34 %
-35.98 %
+26.44 %
-58.20 %
-97.46 %

BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
1.59B SEK
Turnover
5.67M SEK
Revenue
226.5M
EBIT %
-155.27 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/11/2026, 6:00 AM

BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent International
Press release6/11/2026, 6:00 AM

BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

BioInvent International
Press release6/1/2026, 9:00 AM

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/21/2026, 9:00 PM

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent International
Press release5/20/2026, 9:30 AM

BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence® in Relapsed/Refractory NHL at EHA 2026

BioInvent International
Regulatory press release4/29/2026, 3:30 PM

Resolutions at BioInvent’s Annual General Meeting 2026

BioInvent International
Press release4/29/2026, 9:35 AM

BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio

BioInvent International
Regulatory press release4/29/2026, 6:00 AM

BioInvent International AB: Interim report January - March 2026

BioInvent International
Press release4/21/2026, 2:00 PM

BioInvent to Present Data of BI-1808 Plus KEYTRUDA® (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting

BioInvent International
Regulatory press release3/31/2026, 9:45 AM

BioInvent International AB publishes Annual Report 2025

BioInvent International
Press release3/26/2026, 2:27 PM

BioInvent achieves Phase 3 milestone for HMI-115 in endometriosis

BioInvent International
Regulatory press release3/24/2026, 7:00 AM

Notice to Annual General Meeting in BioInvent International AB

BioInvent International
Press release2/27/2026, 1:25 PM

Redeye: BioInvent (Q4 Update): Ovarian a New Value Driver

BioInvent International
BioInvent, Audiocast, Q4'25
Webcast2/26/2026, 1:00 PM

BioInvent, Audiocast, Q4'25

BioInvent International
Regulatory press release2/26/2026, 7:00 AM

BioInvent International AB: Year-end report January 1 – December 31, 2025

BioInvent International
Press release2/26/2026, 6:30 AM

Invitation to presentation of BioInvent’s Year-end report 2025

BioInvent International
Press release2/23/2026, 9:00 AM

BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting

BioInvent International
Press release1/9/2026, 6:57 AM

BioStock: BioInvent reports promising response rate in ovarian cancer

BioInvent International